TR201802935T4 - Stabil sıvı antikor formülasyonu. - Google Patents
Stabil sıvı antikor formülasyonu. Download PDFInfo
- Publication number
- TR201802935T4 TR201802935T4 TR2018/02935T TR201802935T TR201802935T4 TR 201802935 T4 TR201802935 T4 TR 201802935T4 TR 2018/02935 T TR2018/02935 T TR 2018/02935T TR 201802935 T TR201802935 T TR 201802935T TR 201802935 T4 TR201802935 T4 TR 201802935T4
- Authority
- TR
- Turkey
- Prior art keywords
- liquid composition
- antibody
- composition according
- liquid
- less
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 32
- 239000007788 liquid Substances 0.000 title claims abstract 24
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000004220 aggregation Methods 0.000 claims description 3
- 230000002776 aggregation Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical group O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 3
- 229940068977 polysorbate 20 Drugs 0.000 claims 3
- 239000012929 tonicity agent Substances 0.000 claims 3
- 229940074409 trehalose dihydrate Drugs 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 102000046917 human NGF Human genes 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940074410 trehalose Drugs 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Mevcut buluş genellikle antikorlar içeren farmasötik formülasyonların alanı ile ilgilidir. Spesifik olarak mevcut buluş, stabil sıvı bir antikor formülasyonu ve bunun farmasötik preparasyonu ve kullanımı ile ilgilidir. Bu buluş, insancıllaştırılmış bir anti-NGF antikoru içeren bir sıvı formülasyon ile örneklendirilir.
Description
Tarifname içerisinde atifta bulunulan patent dökümanlari:
Tarifnamede belirtilen patentlestirilmemis literatür:
o HONGO et al. Hybridoma, 2000,
° Fundamental lmmunology. Raven
. KABAT. Sequences of Proteins of
o CHOTHIA ; LESK. 1. Mol. Biol.,
- CHOTHIA et al. Nature, 1989, vol.
° SHAW et al. 1 Immunol., 1987, vol.
- BROWN et al. Cancer Res., 1987,
° RIECHMANN et al. Nature, 1988,
° VERHOEYEN et al. Science, 1988,
° JONES et al. Nature, 1986, vol. 321,
° WARD et al. Nature, 1989, vol. 341,
0 BIRD et al. Science, 1988, vol. 242,
° HUSTON et al. Proc. Natl. Acad.
o KABAT et al. Sequences of Proteins
of lmmunological Interest. National
o CHOTHIA et al. Nature, 1989, vol.
° AL-LAZIKANI et al. J. Molec. Biol.,
o WINTER et al. Nature, 1991, vol.
- LOBUGLIO et al. Proc. Nat. Acad.
° Remington, The Science and Practice
of Pharmacy. Mack Publishing, 2000
° KARLSSON, R. ROOS ; H.
FAGERSTAM ; L. PETERSSON,
B. Methods Enzymology, 1994, vol. 6,
99-110 [0159]
- KARLIN ; ALTSCHUL. Proc. Natl.
2268 [0142]
o KARLIN ; ALTSCHUL. Proc. Natl.
5877 [0142]
o ALTSCHUL et al. .1. Mol. Biol.,
o TORELLIS; ROBOTTI. Comput.
o PEARSON ; LIPMAN. Proc. Natl.
. Remington”s Phannaceutical
Sciences. Mack Publishing Co, 1990
- KARLSSON, R. ; ROOS, H. ;
FAGERSTAM, L. ; PETERSSON,B.
Methods Enzymology, 1994, vol. 6, 99-
1 10 [0195]
SEKILLERDEKI YAZILARIN ANLAMLARI
A =Trehaloz
B :Sukroz
C = %Agregasyon
D :Süre (hafta)
E : %Parçalanina
F = Dondurma eritme döngüsü
H :Oksidasyon
3 NF 9 w 0 v N 0
vmrövumî .
omwwwmvwwmowmrwrvvNFOFwovw
..EmeoFiw 4. ov
485& m . m
1:59: om
.:5msom
JEBEQNX
Claims (1)
1. Asagidakileri içeren bir sivi anti-NGF antikoru kompozisyonu: bir antikor, bir tonisite ajani bir tampon, bir kiskaçlama ajani, bir surfektan; burada adi geçen kompozisyonun pH°si, 5.8 ila 6.8 arasindadir, buradaki surfektan, polisorbat 20”dir, buradaki tampon, histidindir, buradaki tonisite ajani, trehalozdur ve buradaki antikor, SEK.KIM.NO.:1°e ait bir degisken agir zincir sekansi ve SEK.KIM.NO.:2”ye ait bir degisken hafif zincir sekansi içerir. Istein l”e göre sivi kompozisyon; buradaki tonisite ajani, trehaloz dihidrattir. Istem 2,ye göre sivi kompozisyon; buradaki trehaloz dihidrat konsantrasyonu, l mg/ml ila 100 mg/ml arasindadir. 1 ila 3 istemlerinden birine göre sivi kompozisyon; buradaki polisorbat 20 konsantrasyonu, 0.01 ila 0.15 mg/ml arasindadir. 1 ila 4 istemlerinden birine göre sivi kompozisyon; buradaki histidin tamponu konsantrasyonu, 1.0 ila 15 mM arasindadir. 1 ila 5 istemlerinden birine göre SlVl kompozisyon; buradaki kiskaçlama ajani, EDTA”dir. Istem 6”ya göre sivi kompozisyon; buradaki EDTA konsantrasyonu, 0.01 ila 0.1 mg/ml arasindadir. 1 ila 7 istemlerinden birine göre sivi kompozisyon; buradaki antikor konsantrasyonu, 50 mg/ml°den az veya buna esittir. 1 ila 8 istemlerinden birine göre olup ayrica bir antioksidan ajan ve/Veya bir prezervatif ajan da içeren sivi kompozisyon. 1 ila 9 istemlerinden birine göre olup, sunlari içeren sivi anti- NGF kompozisyonu: 0.5 ing/inl ila 50 ing/inl antikor, 1.0 mM ila 15 mM histidin tamponu, 1 mg/inl ila 100 mg/ml trehaloz dihidrat, 0.01 ila 0.15 mg/ml polisorbat 20, 0.01 ila 0.] mg/ml EDTA, burada adi geçen kompozisyonun pH”si, 5.8 ila 6.8 arasindadir. 1 ila 10 istemlerinden birine göre sivi kompozisyon; buradaki antikor, bir insan veya insancillastirilmis antikordur. 1 ila 11 istemlerinden birine göre sivi kompozisyon; buradaki 1 ila 112 istemlerinden birine göre sivi kompozisyon; buradaki antikor, insan NGF”sine 2 nM”den az veya buna esit bir KD ile baglanir. 1 ila 13 istemlerindeii birine göre sivi koinpozisyon; buradaki antikor, SEK.KIM.NO.:16°ya ait bir agir zincir amino asit sekansi ve SEK.KIM.NO.:17'ye ait bir hafif zincir amino asit sekansi içerir. 1 ila 114 istemlerinden birine göre sivi kompozisyon; buradaki kompozisyon liyofilize edilmesi ve liyofilizasyona tabi tutulmamistir. 1 ila 15 istemlerinden birine göre sivi kompozisyon; buradaki kompozisyon, birçok dondurma eritme döngüsünden sonra antikor agregasyonuna dirençlidir. 1 ila 15 istemleriiiden birine göre sivi kompozisyon; buradaki kompozisyon, 40°C°1ik bir sicaklikta en az 26 haftalik bir süre boyunca depolanabilir ve burada: (a) kompozisyonun antikorunda %10”dan az agregasyon artisi, (b) kompozisyonun antikorunda %10”dan az oksidasyon artisi (c) kompozisyonun antikorunda %10”dan az aktivite düsüsü 1 ila 17 istemlerinden birine göre sivi kompozisyon; buradaki kompozisyon, 40°C”lik bir sicaklikta en az 26 haftalik bir sure boyunca depolanabilir ve buradaki koinpozisyonun antikorunda Bir memelide agri tedavisinde kullanim için 1 ila 18 istemlerinden birine göre sivi kompozisyon. Istem 19”a göre kullanim için sivi kompozisyon; buradaki koinpozisyonun uygulanma paterni, bir doz koinpozisyonun sekiz haftada bir uygulanmasini kapsar. Istem 20”ye göre kullanim için sivi kompozisyon; buradaki doz hacmi, 2.5 m1`den az veya buna esittir. Istem 20 yada istein 21 ”e göre kullanim için sivi kompozisyon; buradaki doz, 50 mg°den az veya buiia esit antikor içerir. 20 ila 22 istenilerinden birine göre kullanim için sivi kompozisyon; buradaki doz uygulamasi, intravenöz veya subkütandir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9830508P | 2008-09-19 | 2008-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201802935T4 true TR201802935T4 (tr) | 2018-03-21 |
Family
ID=41566226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/02935T TR201802935T4 (tr) | 2008-09-19 | 2009-09-18 | Stabil sıvı antikor formülasyonu. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10188600B2 (tr) |
| EP (2) | EP2331090B1 (tr) |
| JP (1) | JP5642683B2 (tr) |
| KR (1) | KR101355750B1 (tr) |
| CN (1) | CN102159204B (tr) |
| AU (1) | AU2009294214B2 (tr) |
| BR (1) | BRPI0917888A2 (tr) |
| CA (1) | CA2736864C (tr) |
| DK (1) | DK2331090T3 (tr) |
| ES (1) | ES2658596T3 (tr) |
| HK (1) | HK1160389A1 (tr) |
| HU (1) | HUE036126T2 (tr) |
| IL (1) | IL211295A (tr) |
| MX (1) | MX2011003013A (tr) |
| PL (1) | PL2331090T3 (tr) |
| PT (1) | PT2331090T (tr) |
| RU (1) | RU2518278C2 (tr) |
| SI (1) | SI2331090T1 (tr) |
| TR (1) | TR201802935T4 (tr) |
| WO (1) | WO2010032220A1 (tr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921578C (en) | 2002-12-24 | 2017-02-14 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
| US9498530B2 (en) * | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| MX2012010198A (es) | 2010-03-01 | 2012-10-03 | Bayer Healthcare Llc | Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi). |
| US20110256135A1 (en) * | 2010-03-17 | 2011-10-20 | Wolfgang Fraunhofer | Anti-nerve growth factor (ngf) antibody compositions |
| RU2600847C2 (ru) * | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| CN103476796A (zh) | 2011-01-28 | 2013-12-25 | 赛诺菲 | 治疗特定受试者组的方法中使用的针对pcsk9的人抗体 |
| KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
| TW201247222A (en) * | 2011-04-21 | 2012-12-01 | Daiichi Sankyo Co Ltd | Antibody liquid formulation |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EP3536712B1 (en) | 2011-09-16 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
| WO2013186230A1 (en) * | 2012-06-12 | 2013-12-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| CA2878508A1 (en) * | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| CN102863948B (zh) * | 2012-10-14 | 2014-08-13 | 东北石油大学 | 一种驱油用羟磺基甜菜碱两性表面活性剂及其制备方法 |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
| MX365567B (es) | 2013-03-13 | 2019-06-07 | Genentech Inc | Formulaciones de anticuerpo. |
| US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
| WO2014160495A1 (en) * | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Formulations with reduced oxidation |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EA201592267A1 (ru) | 2013-06-07 | 2016-04-29 | Ридженерон Фармасьютикалз, Инк. | Способы ингибирования атеросклероза посредством введения ингибитора pcsk9 |
| AU2014348765A1 (en) | 2013-11-12 | 2016-06-09 | Regeneron Pharmaceuticals, Inc. | Dosing regimens for use with PCSK9 inhibitors |
| JP2017528427A (ja) | 2014-07-16 | 2017-09-28 | サノフィ・バイオテクノロジー | ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法 |
| JP7072384B2 (ja) | 2014-09-15 | 2022-05-20 | ジェネンテック， インコーポレイテッド | 抗体製剤 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| CN107922507B (zh) | 2015-08-18 | 2022-04-05 | 瑞泽恩制药公司 | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 |
| JPWO2017164349A1 (ja) | 2016-03-25 | 2019-02-07 | アステラス製薬株式会社 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
| AU2017345490B2 (en) * | 2016-10-21 | 2022-07-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| CA3050172A1 (en) * | 2017-01-19 | 2018-07-26 | Bayer Pharma Aktiengesellschaft | Novel stable formulation for fxia antibodies |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CA3064550A1 (en) * | 2017-06-16 | 2018-12-20 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
| JP2020117502A (ja) | 2019-01-28 | 2020-08-06 | ファイザー・インク | 変形性関節症の徴候および症状を処置する方法 |
| WO2020170103A1 (en) | 2019-02-18 | 2020-08-27 | Pfizer Inc. | Method of treatment of chronic low back pain |
| EP3927729A4 (en) | 2019-02-18 | 2023-10-11 | Eli Lilly and Company | THERAPEUTIC ANTIBODY FORMULATION |
| US20220314142A1 (en) | 2019-07-01 | 2022-10-06 | Pfizer Inc. | Improvements to wash solutions for protein a chromatography in an antibody purification process |
| TW202136777A (zh) | 2019-12-20 | 2021-10-01 | 美商輝瑞股份有限公司 | 內毒素偵測 |
| JP2023525898A (ja) * | 2020-05-19 | 2023-06-19 | エフ． ホフマン－ラ ロシュ アーゲー | 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用 |
| CN113797333A (zh) * | 2020-06-12 | 2021-12-17 | 上海君实生物医药科技股份有限公司 | 一种新型冠状病毒抗体的药物组合物及其用途 |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
| WO2023007374A1 (en) | 2021-07-27 | 2023-02-02 | Pfizer Inc. | Method of treatment of cancer pain with tanezumab |
| WO2023212586A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| CN116239677B (zh) * | 2023-03-31 | 2023-08-29 | 优睿赛思(武汉)生物科技有限公司 | 一种重组抗体纯化方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| DE69408541T2 (de) | 1993-11-23 | 1998-08-06 | Genentech Inc | Kinaserezeptoraktivierungstest |
| AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| DE60335957D1 (de) * | 2002-10-08 | 2011-03-17 | Rinat Neuroscience Corp | Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen |
| CA2921578C (en) * | 2002-12-24 | 2017-02-14 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| WO2004065560A2 (en) | 2003-01-18 | 2004-08-05 | Rinat Neuroscience Corp. | Methods of screening for modulators of nerve growth factor |
| DK1648509T3 (da) | 2003-07-15 | 2013-01-07 | Amgen Inc | Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer |
| JP2006054422A (ja) * | 2004-07-15 | 2006-02-23 | Fuji Photo Film Co Ltd | 有機電界発光素子及び表示素子 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2600601A1 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Anti-m-csf antibody compositions having reduced levels of endotoxin |
| AR062247A1 (es) * | 2005-03-08 | 2008-10-29 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos anti-ctla-4 |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| EP2572729A3 (en) | 2007-08-10 | 2013-06-05 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
-
2009
- 2009-09-18 ES ES09787253.5T patent/ES2658596T3/es active Active
- 2009-09-18 DK DK09787253.5T patent/DK2331090T3/en active
- 2009-09-18 KR KR1020117008909A patent/KR101355750B1/ko active IP Right Grant
- 2009-09-18 PT PT97872535T patent/PT2331090T/pt unknown
- 2009-09-18 RU RU2011108025/10A patent/RU2518278C2/ru active
- 2009-09-18 EP EP09787253.5A patent/EP2331090B1/en active Active
- 2009-09-18 HU HUE09787253A patent/HUE036126T2/hu unknown
- 2009-09-18 CA CA2736864A patent/CA2736864C/en not_active Expired - Fee Related
- 2009-09-18 JP JP2011527455A patent/JP5642683B2/ja active Active
- 2009-09-18 EP EP17209015.1A patent/EP3329911A1/en not_active Withdrawn
- 2009-09-18 MX MX2011003013A patent/MX2011003013A/es active IP Right Grant
- 2009-09-18 CN CN200980136824.9A patent/CN102159204B/zh active Active
- 2009-09-18 SI SI200931813T patent/SI2331090T1/en unknown
- 2009-09-18 US US13/119,784 patent/US10188600B2/en active Active
- 2009-09-18 PL PL09787253T patent/PL2331090T3/pl unknown
- 2009-09-18 WO PCT/IB2009/054111 patent/WO2010032220A1/en active Application Filing
- 2009-09-18 TR TR2018/02935T patent/TR201802935T4/tr unknown
- 2009-09-18 BR BRPI0917888-0A2A patent/BRPI0917888A2/pt not_active Application Discontinuation
- 2009-09-18 AU AU2009294214A patent/AU2009294214B2/en not_active Ceased
-
2011
- 2011-02-17 IL IL211295A patent/IL211295A/en active IP Right Grant
-
2012
- 2012-01-29 HK HK12100829A patent/HK1160389A1/xx not_active IP Right Cessation
-
2018
- 2018-12-14 US US16/220,442 patent/US20190314272A1/en not_active Abandoned
-
2021
- 2021-07-16 US US17/378,025 patent/US20220175663A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2658596T3 (es) | 2018-03-12 |
| HUE036126T2 (hu) | 2018-06-28 |
| CA2736864C (en) | 2020-10-13 |
| RU2011108025A (ru) | 2012-10-27 |
| AU2009294214A1 (en) | 2010-03-25 |
| HK1160389A1 (en) | 2012-08-17 |
| DK2331090T3 (en) | 2018-03-12 |
| PL2331090T3 (pl) | 2018-05-30 |
| EP3329911A1 (en) | 2018-06-06 |
| US10188600B2 (en) | 2019-01-29 |
| BRPI0917888A2 (pt) | 2014-02-25 |
| EP2331090B1 (en) | 2018-01-03 |
| IL211295A0 (en) | 2011-04-28 |
| RU2518278C2 (ru) | 2014-06-10 |
| MX2011003013A (es) | 2011-04-11 |
| US20190314272A1 (en) | 2019-10-17 |
| US20220175663A1 (en) | 2022-06-09 |
| IL211295A (en) | 2016-05-31 |
| WO2010032220A1 (en) | 2010-03-25 |
| US20110171217A1 (en) | 2011-07-14 |
| JP5642683B2 (ja) | 2014-12-17 |
| JP2012502976A (ja) | 2012-02-02 |
| CN102159204A (zh) | 2011-08-17 |
| SI2331090T1 (en) | 2018-04-30 |
| CN102159204B (zh) | 2015-04-01 |
| EP2331090A1 (en) | 2011-06-15 |
| KR101355750B1 (ko) | 2014-01-27 |
| PT2331090T (pt) | 2018-02-07 |
| KR20110056422A (ko) | 2011-05-27 |
| CA2736864A1 (en) | 2010-03-25 |
| AU2009294214B2 (en) | 2014-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201802935T4 (tr) | Stabil sıvı antikor formülasyonu. | |
| RU2639386C2 (ru) | УЛУЧШЕННЫЕ ВЫСОКОКОНЦЕТРИРОВАННЫЕ ЖИДКИЕ ПРЕПАРАТЫ АНТИТЕЛ ПРОТИВ TNF-альфа | |
| JP7404256B2 (ja) | 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 | |
| HRP20171217T1 (hr) | Stabilni pripravak koji sadrži pthrp i njegova upotreba | |
| KR102359181B1 (ko) | 항-ｒｓｖ 모노클로날 항체 제제 | |
| JP2012526121A5 (tr) | ||
| JP2008520551A5 (tr) | ||
| CA2794929A1 (en) | Concentrated protein formulations and uses thereof | |
| KR20100126469A (ko) | 미노사이클린 화합물 및 이들의 사용 방법 | |
| HRP20230462T1 (hr) | Supkutana formulacija protutijela anti-her2 | |
| ES2843277T3 (es) | Aplicación tópica para un anticuerpo anti-VHS | |
| BR112019018022A2 (pt) | Formulações de anticorpos monoclonais | |
| RU2019100887A (ru) | Композиции антитела и белка | |
| JP2013500947A5 (tr) | ||
| JP2018502910A (ja) | Ｉｌ−１７抗体の医薬製品および安定した液体組成物 | |
| KR20170044211A (ko) | 항체 제제 | |
| ES2925232T3 (es) | Proceso para la formulación farmacéutica liofilizada de una proteína terapéutica | |
| WO2021079337A1 (en) | Pharmaceutical formulation of anti-her2 antibody and preparation thereof | |
| RU2020112302A (ru) | Соединения для уменьшения вязкости биологических композиций | |
| JP7467438B2 (ja) | 抗ｒｓｖ抗体の製剤及びその使用方法 | |
| US20220073628A1 (en) | Anti-il-36r antibodies for the treatment of neutrophilic dermatoses | |
| RU2007133661A (ru) | КОМПОЗИЦИИ АНТИТЕЛ К MAdCAM | |
| KR102668158B1 (ko) | 항-ｒｓｖ 모노클로날 항체 제제 | |
| JP2020531523A5 (tr) | ||
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 |